Peroxisome proliferator-activated receptor γ (PPARγ) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the β-catenin/T cell factor (TCF) pathway

Journal of Pharmacological Sciences

Volumn 106, Issue 4, 2008, Pages 627-638

  Fujisawa, Toshio ^a   Nakajima, Atsushi ^a,b   Fujisawa, Nobutaka ^a   Takahashi, Hirokazu ^a   Ikeda, Ikuko ^a   Tomimoto, Ayako ^a   Yonemitsu, Kyoko ^a   Nakajima, Noriko ^c   Kudo, Chiho ^d   Wada, Koichiro ^d   Kubota, Naoto ^e   Terauchi, Yasuo ^a   Kadowaki, Takashi ^e   Nakagama, Hitoshi ^f   Blumberg, Richard S ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Colon cancer; Epithelial cell turnover; Peroxisome proliferator activated receptor (PPAR ); catenin

Indexed keywords

AZOXYMETHANE; BETA CATENIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TRANSCRIPTION FACTOR 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STAGING; COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; COLON POLYP; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENETIC PREDISPOSITION; INHIBITION KINETICS; INSULIN SENSITIVITY; LIGAND BINDING; LIPID METABOLISM; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION;

EID: 42349115929     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071766     Document Type: Article

References (38)

1. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354-366.
2. Lemberger T, Braissant O, Juge-Aubry C, Keller H, Saladin R, Staels B, et al. PPAR tissue distribution and interactions with other hormone-signaling pathways. Ann N Y Acad Sci. 1996;804:231-251.
3. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.
4. Chawla A, Schwarz EJ, Dimaculangan DD, Lazer MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 1994;135:798-800.
5. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147-1156.
6. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998;101:1354-1361.
7. Cantello BC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, et al. [[omega-(Heterocyclylamino) alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem. 1994;37:3977-3985.
8. 2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-812.
9. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 1997;272:18779-18789.
10. Suzawa M, Takada I, Yanagisawa J, Ohtake F, Ogawa S, Yamauchi T, et al. Cytokine suppresses adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat Cell Biol. 2003;5:224-230.
11. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis. 1998;19:49-53.
12. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 1998;4:1053-1057.
13. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998;4:1058-1061.
14. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998;4:1046-1052.
15. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology. 2003;124:361-367.
16. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, et al. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 2001;61:2424-2428.
17. Niho N, Takahashi M, Shoji Y, Takeuchi Y, Matsubara S, Sugimura T, et al. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci. 2003;94:960-964.
18. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res. 2003;63:6090-6095.
19. Kiecker C, Niehrs C. Amorphogen gradient of Wnt/beta-catenin signaling regulates anteroposterior neural patterning in Xenopus. Development. 2001;128:4189-4201.
20. Watson SA. Oncogenic targets of beta-catenin-mediated transcription in molecular pathogenesis of intestinal polyposis. Lancet. 2001;357:572-573.
21. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103:311-320.
22. Kwong KY, Zou Y, Day CP, Hung MC. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. Oncogene. 2002;21:8340-8346.
23. Wilson AJ, Velcich A, Arango D, Kurland AR, Shenoy SM, Pezo RC, et al. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002;62:6006-6010.
24. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422-426.
25. Alrawi SJ, Schiff M, Carroll RE, Dayton M, Gibbs JF, Kulavlat M, et al. Aberrant Crypt Foci. Anticancer Res. 2006;26:107-119.
26. Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A. 2002;99:13771-13776.
27. Carbone GM, McGuffie E, Napoli S, Flanagan CE, Dembech C, Negri U, et al. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene. Nucleic Acids Res. 2004;32:2396-2410.
28. Jung C, Kim RS, Lee SJ, Wang C, Jeng MH. HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Cancer Res. 2004;64:3046-3051.
29. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999;4:597-609.
30. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
31. Roncucci L, Pedroni M, Vaccina F, Benatti P, Marzona L, De Pol A. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Proliferations. 2000;33:1-18.
32. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643-649.
33. Risio M, Coverlizza S, Ferrari A, Cadelaresi GL, Rossini FP. Immunohistochemical study of epithelial cell proliferation in hyperplastic polyps, adenomas, and adenocarcinomas of the large bowel. Gastroenterology. 1988;94:899-906.
34. Deschner EE, Maskens AP. Significance of the labeling index and labeling distribution as kinetic parameters in colorectal mucosa of cancer patients and DMH treated animals. Cancer. 1982;50:1136-1141.
35. Macarthur M, Hold GL, EL-Omar EM. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointestinal Liver Physiol. 2004;286:G515-G520.
36. Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett. 2006;240:225-233.
37. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology. 2001;120:460-469.
38. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut. 2002;50:658-664.